Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial

L Pedersen; L L Christensen; S M Pedersen; M Andersen

doi:10.1007/s40618-016-0597-3

Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial

L Pedersen^*, L L Christensen, S M Pedersen, M Andersen

^*Corresponding author af dette arbejde

Klinisk Biokemisk Afdeling

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.

DESIGN: Randomized, double-blinded, placebo-controlled study.

SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men.

PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.

INTERVENTION: Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo.

RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.

CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.

Originalsprog	Engelsk
Sider (fra-til)	529-538
Antal sider	10
Tidsskrift	Journal of endocrinological investigation
Vol/bind	40
Udgave nummer	5
DOI	https://doi.org/10.1007/s40618-016-0597-3
Status	Udgivet - maj 2017

Adgang til dokumentet

10.1007/s40618-016-0597-3

Citationsformater

@article{4f461cb96d7b48a3ab70afbbf32d24cc,

title = "Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial",

abstract = "OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.DESIGN: Randomized, double-blinded, placebo-controlled study.SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men.PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.INTERVENTION: Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim{\textregistered}, Ipsen, France) or 5-10 g gel/placebo.RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.",

keywords = "Aged, Aging/drug effects, Androgens/administration & dosage, Double-Blind Method, Female, Fibroblast Growth Factor-23, Follow-Up Studies, Humans, Leukocyte L1 Antigen Complex/blood, Male, Middle Aged, Phosphates/blood, Prognosis, Risk Factors, Testosterone/administration & dosage",

author = "L Pedersen and Christensen, {L L} and Pedersen, {S M} and M Andersen",

year = "2017",

month = may,

doi = "10.1007/s40618-016-0597-3",

language = "English",

volume = "40",

pages = "529--538",

journal = "Journal of endocrinological investigation",

issn = "0391-4097",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Reduction of calprotectin and phosphate during testosterone therapy in aging men

T2 - a randomized controlled trial

AU - Pedersen, L

AU - Christensen, L L

AU - Pedersen, S M

AU - Andersen, M

PY - 2017/5

Y1 - 2017/5

N2 - OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.DESIGN: Randomized, double-blinded, placebo-controlled study.SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men.PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.INTERVENTION: Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo.RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.

AB - OBJECTIVES: To investigate the effect of testosterone treatment on biomarkers calprotectin, fibroblast growth factor 23 (FGF23), soluble Klotho, phosphate, calcium, parathyroid hormone, creatinine and estimated glomerular filtration rate.DESIGN: Randomized, double-blinded, placebo-controlled study.SETTING: Odense Androgen Study-the effect of Testim and training in hypogonadal men.PARTICIPANTS: Men aged 60-78 years old with a low normal concentration of free of bioavailable testosterone <7.3 nmol/L and waist circumference >94 cm recruited from 2008 to 2009 (N = 48) by advertisement.INTERVENTION: Participants were randomized to receive 5-10 g gel/50-100 mg testosterone (Testim®, Ipsen, France) or 5-10 g gel/placebo.RESULTS: The plasma levels of calprotectin and phosphate were significantly reduced in the group receiving testosterone therapy (gel) compared to the placebo group (p < 0.05). Testosterone treatment did not have any significant effect on plasma levels of FGF23 or soluble Klotho. The reduction in phosphate levels was inversely associated with bioavailable testosterone.CONCLUSION: Compared to the placebo group, 6 months of testosterone therapy (gel) reduced calprotectin and phosphate levels suggesting decreased inflammation and decreased cardiovascular risk.

KW - Aged

KW - Aging/drug effects

KW - Androgens/administration & dosage

KW - Double-Blind Method

KW - Female

KW - Fibroblast Growth Factor-23

KW - Follow-Up Studies

KW - Humans

KW - Leukocyte L1 Antigen Complex/blood

KW - Male

KW - Middle Aged

KW - Phosphates/blood

KW - Prognosis

KW - Risk Factors

KW - Testosterone/administration & dosage

U2 - 10.1007/s40618-016-0597-3

DO - 10.1007/s40618-016-0597-3

M3 - Article

C2 - 28000180

SN - 0391-4097

VL - 40

SP - 529

EP - 538

JO - Journal of endocrinological investigation

JF - Journal of endocrinological investigation

IS - 5

ER -

Reduction of calprotectin and phosphate during testosterone therapy in aging men: a randomized controlled trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater